Navigation Links
Marker identifies breast cancer patients likely to respond to tamoxifen
Date:5/18/2011

PHILADELPHIACancer researchers at the Kimmel Cancer Center at Jefferson and an international team of collaborators have discovered a biomarker in breast cancer that may help identify which women will respond to anti-estrogen therapy.

The research appears in the May 16 online issue of the Journal of Clinical Oncology.

Anti-estrogen drugs, most notably tamoxifen, are widely used in patients diagnosed with estrogen receptor-positive breast cancer. However, as many as a third of the women given tamoxifen fail to respond.

In this new study, the investigators found that women whose tumors retain the active form of the protein biomarker Stat5 have an increased likelihood of responding to tamoxifen. In contrast, women treated with tamoxifen whose tumors lacked active Stat5 had up to a 20-fold increased risk of dying from breast cancer after adjustment for effects of standard hormone receptor markers and other pathology data.

"Identification of predictive biomarkers present in breast cancer will lead to improved individualized therapies tailored specifically towards each woman's cancer," said Hallgeir Rui, M.D., Ph.D., professor of oncology, Kimmel Cancer Center at Thomas Jefferson University, and principal investigator of the study. "Absence of the active form of Stat5 could help identify a group of patients unlikely to respond to tamoxifen so they may be offered alternative and more aggressive treatments."

Stat5 protein is a DNA-binding factor that regulates expression of certain genes, many of which remain unknown. During pregnancy, Stat5 is activated by the hormone prolactin, and stimulates milk production in the breast. Active Stat5 is also detectable at lower levels in healthy breast tissue of non-pregnant women. This study further showed that active Stat5 was lost in the majority of more aggressive tumors and when those tumors metastasized to lymph nodes.

In 2004, Rui and colleagues reported that women with early stage breast cancer had higher survival rates when their tumors expressed active Stat5. Therefore, in two independent groups of breast cancer patients that were not treated with chemotherapy or anti-estrogen therapy, they further investigated the relationship between active Stat5 in the tumor and whether the patient had breast cancer recurrence or died of breast cancer over periods as long as 30 years. The team found consistent favorable breast cancer outcomes when tumors retained active Stat5.

The studies presented in this publication utilized a retrospective analysis of five large, independent breast cancer patient materials that included 1,000 patients, giving the studies a solid statistical basis. A benefit of optimizing a marker like Stat5 is that the assay for Stat5 is simple, inexpensive, and can be rapidly adapted to routine analysis in pathology laboratories using standard procedures.

"More work remains to be done, but we are optimistic about the utility of Stat5 as a biomarker," said Amy Peck, PhD, and lead author of the study. "The team is moving forward with plans for a randomized, prospective study with larger patient numbers to further evaluate the utility of Stat5 in managing and treating breast cancer."


'/>"/>

Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Marker of Ewing sarcoma: Potential new drug target?
2. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
3. Personalizing cancer: Creating biomarkers from tumor DNA
4. Damaged protein identified as early diagnostic biomarker for Alzheimers disease in healthy adults
5. Reliable biomarkers needed for early detection of liver cancer
6. More Reliable Biomarkers Needed for Early Detection of Liver Cancer
7. Voyant Health, Ltd. Announces the Launch of KingMark™, a Pioneering Calibration Marker that Calculates the Radiological Magnification of the Hip
8. UAB researchers find 4 biomarkers important in colerectal cancer treatment prognosis
9. BATTLE links potential biomarkers to drugs for lung cancer
10. UAB researchers find 4 biomarkers important in colorectal cancer treatment prognosis
11. Increased EGFR levels may be an early marker of breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... ... the ATA 2017 President’s Awards recipients, comprised of organizations and individuals who ... , The ATA 2017 President’s Awards recognize individuals and organizations on ...
(Date:4/26/2017)... Aviv, Israel (PRWEB) , ... April 26, 2017 , ... ... today announced a new partnership with Med-e-Mass , the largest Electronic Medical Records ... enable Med-e-Mass to link care plan incentives to a patient’s remote health progress, empowering ...
(Date:4/26/2017)... ... 26, 2017 , ... The National Business Research Institute (NBRI) ... of Emergency Medical Technicians and welcomes this organization to the NBRI Circle ... West, Ph.D. , CEO & Organizational Psychologist at NBRI. “This award is a ...
(Date:4/26/2017)... ... 2017 , ... Miami native and local periodontist Dr. John Paul Gallardo ... imagined back in 1991 that this journey would have taken me into so many ... years, Dr. Gallardo has pioneered implant dentistry innovation, evolving into an internationally recognized leader ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more ... CRISPRCas.pioneer.com ) that demonstrates how this advanced plant breeding technology is a more ... with fewer resources. It highlights the business’ principles, research and collaboration efforts in ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... product development program, based on its proprietary self-delivering ... Dermatology (SID) 76 th Annual Meeting.  The ... sciences relevant to skin health and disease through ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive ... offering. ... market was valued at US$ 7,167.6 Mn in 2015, and ... at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
Breaking Medicine Technology: